Evidence review

SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review

Posted Jun 29, 2026 · Updated Jul 17, 2026 · 4 min read

What's breaking down if you have Plantar fasciitis

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why SS-31 (Elamipretide) might help you

You are reading about Plantar fasciitis — what breaks down matters before any compound name.
Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

SS-31 (Elamipretide) → mitochondrial

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 2
Claims tagged human evidence: 2
Claims tagged preclinical (animal/lab): 2
Claims tagged anecdotal: 1
Reddit posts catalogued: 0
X posts catalogued: 0
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 3

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.39 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model (source s1)

In vitro study on human tenocytes showing SS-31 effects on mitochondria and gene expression in degenerative cells.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

PubMed.gov

Study

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model

In vitro study on human tenocytes showing SS-31 effects on mitochondria and gene expression in degenerative cells.

2026-06-29 23:48s1 · #f097611dea88

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model (source s2)

Explicit statement of no prior exploration in tendinopathy, extending to plantar fasciitis.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model

Explicit statement of no prior exploration in tendinopathy, extending to plantar fasciitis.

2026-06-29 23:48s2 · #27a377688ad1

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 3 sources · swipe →chain 1e32ffca2ef4 · verify chain · provenance

1 / 3

PubMed.gov

Study

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model

In vitro study on human tenocytes showing SS-31 effects on mitochondria and gene expression in degenerative cells.

2026-06-29 23:48s1 · #f097611dea88

PubMed.gov

Study

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model

Explicit statement of no prior exploration in tendinopathy, extending to plantar fasciitis.

2026-06-29 23:48s2 · #27a377688ad1

FIGHTAGING.ORG

FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31

Reports 2025 FDA approval for Barth syndrome and trial context.

Jun 29, 2026

2026-06-29 23:48s3 · #1e32ffca2ef4

Evidence ledger 5 · tier-ranked · API

human

No human clinical trials of SS-31 have been conducted in plantar fasciitis.

sources: s2

preclinical

Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture.

sources: s1

preclinical

SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocytes.

sources: s1

anecdotal

No Reddit or X anecdotes mention SS-31 for plantar fasciitis.

humanlow confidence

SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements.

sources: s3

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-29 23:48

SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review · 5 claims · 3 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: Ss 31 for Plantar Fasciitis
Slug: ss-31-plantar-fasciitis
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"Plantar fasciitis","condition_key":"plantar-fasciitis","primary_peptide":"ss-31","peptides_in_scope":[{"id":"ss-31","name":"SS-31 (Elamipretide)"}],"drugs_in_scope":[],"weight_sensitive":true,"stimulant_context":false,"breaking_down":{"section_title":"

it output

{
  "slug": "ss-31-plantar-fasciitis",
  "title": "SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review",
  "body": "## What's breaking down if you have Plantar Fasciitis\n\nPlantar fasciitis involves degenerative changes in the plantar fascia, the thick band of tissue connecting your heel bone to your toes. The tissue shows collagen disorganization, increased cell death in tenocyte-like cells, and reduced ability to handle mechanical stress from walking or standing.\n\nIf your fascia cells have mitochondrial dysfunction, energy production drops and repair slows. This creates a gap where breakdown outruns regeneration. Mitochondrial membrane potential falls, reactive oxygen species handling weakens, and genes linked to matrix breakdown rise. These layers matter because plantar fascia is under constant load; poor cellular energy makes recovery harder.\n\nNo direct human data links plantar fasciitis to SS-31. The closest evidence comes from degenerative tendon cells, which share features with fascia degeneration.\n\n## Why SS-31 (Elamipretide) might help you\n\n1. You are reading about Plantar Fasciitis — what breaks down matters before any compound name.\n2. Therefore for you: If mitochondrial dysfunction in fascia cells is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.\n\nSS-31 concent

f3d7ac422dfb8fbf

Machine verification: /api/articles/ss-31-plantar-fasciitis/contributions

Ask this article · 7 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No human clinical trials of SS-31 have been conducted in plantar fasciitis."?

ask ss-31-plantar-fasciitis claim c3 · paste includes §SELF

What does the ledger say about this (preclinical tier): "Degenerative tenocytes from human tendon show increased mitochondrial depolarization that decreases after SS-31 treatment in cell culture."?

ask ss-31-plantar-fasciitis claim c1 · paste includes §SELF

What does the ledger say about this (preclinical tier): "SS-31 improved mitochondrial morphology, superoxide dismutase activity, and reduced MMP-1 and FABP4 gene expression in degenerative tenocyte…"?

ask ss-31-plantar-fasciitis claim c2 · paste includes §SELF

What does the ledger say about this (anecdotal tier): "No Reddit or X anecdotes mention SS-31 for plantar fasciitis."?

ask ss-31-plantar-fasciitis claim c5 · paste includes §SELF

What does the ledger say about this (human tier): "SS-31 received FDA approval for Barth syndrome in 2025 based on extension-phase functional improvements."?

ask ss-31-plantar-fasciitis claim c4 · paste includes §SELF

For my medical situation, what can you answer from your catalogue about SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review — and what would you need me to tell you first?

ask ss-31-plantar-fasciitis condition gaps · paste includes §SELF

What good and bad outcomes are documented for SS-31 (Elamipretide) for Plantar Fasciitis: Mitochondrial Evidence Review (studies vs anecdotes)?

ask ss-31-plantar-fasciitis good bad experiences · paste includes §SELF

What's breaking down if you have Plantar fasciitis

Why SS-31 (Elamipretide) might help you

How these fit together

What the evidence actually shows

What scientists say

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model (source s1)

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model (source s2)

Connected articles

Related articles